Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421716 · ClinicalTrials.gov registry record · Early Phase 1
Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid
A Early Phase 1 study of Bioavailability of Phytonutrients, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04421716: Completed Early Phase 1 study of Bioavailability of Phytonutrients, sponsored by The University of Texas Health Science Center at San Antonio.
NCT04421716 is a Early Phase 1 study of Bioavailability of Phytonutrients that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 18 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421716, a Early Phase 1 study of Bioavailability of Phytonutrients, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this research is to investigate the bioavailability of curcumin (CURC) and ursolic acid (UA) in a phase I clinical trial in healthy men and obtain biological material for bioavailability analysis.
Primary Outcome
Safety will be compared to evaluate the number, frequency, duration, and relation of toxicity events to CURC and UA, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) v 4.03.
Conditions Studied
Interventions
- DRUG Curcumin
- DRUG Ursolic Acid
Study Locations (1)
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2021-04-16 |
| Phase | Early Phase 1 |
What the finished NCT04421716 record still lists
NCT04421716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Bioavailability of Phytonutrients appearing as the primary indexed condition, and to 2 interventions - of which Curcumin is the first listed.
NCT04421716 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04421716 about?
NCT04421716 is a clinical study titled "Testing the Bioavailability of Phytonutrients, Curcumin and Ursolic Acid". The primary objective of this research is to investigate the bioavailability of curcumin (CURC) and ursolic acid (UA) in a phase I clinical trial in healthy men and obtain biological material for bioavailability analysis.
What is the current status of trial NCT04421716?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2020-10-20. Estimated completion is 2021-04-16.
What conditions does trial NCT04421716 study?
This clinical trial studies the following conditions: Bioavailability of Phytonutrients.
What interventions are being tested in trial NCT04421716?
The interventions under investigation include: Curcumin (DRUG), Ursolic Acid (DRUG).
Who is sponsoring clinical trial NCT04421716?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04421716 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04421716's enrollment target sits among peer trials
18 1316th of 2000 higher than 651 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI